Most available support is preclinical, mechanistic or anecdotal. Human efficacy and long-term safety are not established.
Overview
Thymosin Alpha-1 (thymalfasin) is a naturally occurring immune-regulating peptide. Unlike most research peptides, it is an approved medicine in a number of countries (as Zadaxin) for certain viral and immune indications.
How It's Thought to Work
It modulates immune function, including effects on T-cell activity and inflammatory signaling.
What the Research Says
It has a genuine clinical evidence base for its approved uses (e.g., hepatitis, immune support), studied in multiple countries.
Key studies to start with
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review
Pharmaceuticals (Basel, Switzerland) · 2026 Sep 19
PubMedThymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026 Sep 3
Regulatory & Legal Status
Approved in various countries (not broadly FDA-approved in the US). US 'research chemical' versions are unapproved.
Safety Considerations
Approved use has an established safety profile; unregulated gray-market products carry added risk. Consult a qualified clinician.